Overview

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation. Additionally, liquid formulation pharmacokinetics, including a comparison of fed and fasted pharmacokinetics, of the liquid formulation will be performed in a subset of subjects.

Phase:

Phase 3

Details

Lead Sponsor:

Mallinckrodt
Sucampo AG

Collaborators:

Sucampo AG
Sucampo Pharma Americas, LLC
Takeda

Treatments:

Lubiprostone